Shilpa Medicare bags initial European authorization for Rotigotine Transdermal Patch for Parkinson's disease
Shilpa's Rotigotine patches are indicated for treatment of Restless Legs Syndrome and Parkinson's disease.
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2025-12-12 09:44 GMT | Update On 2025-12-12 09:44 GMT
Advertisement
Karnataka: Shilpa Medicare Limited has received the Initial Authorization from Europe, recommending the grant of the final Marketing Authorization for the company’s prescription product, Rotigotine 1, 2, 3, 4, 6, 8 mg/24 h transdermal patch.
This application, submitted as a generic application via Decentralized Procedure in Europe and is a generic version of the innovator product Neupro. Shilpa’s product is pharmaceutical and bioequivalent version of the reference product Neupro.
Read also: Shilpa Medicare Telangana facility receives 8 USFDA observations
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.